Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | TP53 | P04637 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | GFER | P55789 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.64 |
| ▸ | RELA | Q04206 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800390 | 0.94 | RAB9A (0.72) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14947174 | 0.94 | NPC1 (0.75) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15745637 | 0.92 | NPC1 (0.73) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3288472 | 0.92 | NPC1 (0.78) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28331595 | 0.91 | NPC1 (0.77) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10045308 | 0.88 | NPC1 (0.68) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2242200 | 0.87 | RAB9A (0.84) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3368896 | 0.87 | ESR1 (0.69) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22103728 | 0.87 | NPC1 (0.66) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2244484 | 0.87 | NPC1 (0.66) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-0280652-B1 | PROCESS FOR INCREASING THE DEGREE OF WHITENESS OF TEXTILE MATERIAL CONTAINING A POLYESTER | CIBA-GEIGY AG (CH) | 1992-09-16 | — | — | EP | claimed |
| EP-0280652-A1 | Process for increasing the degree of whiteness of textile material containing a polyester | CIBA-GEIGY AG (CH) | 1988-08-31 | — | — | EP | claimed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7723114-B1 | Methods and systems for detection of radionuclides | CLEMSON UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| WO-2000077545-A1 | IN-SITU RADIOACTIVITY DETECTION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6139749-A | CONTACTING ENVIRONMENTAL FLUID WITH COMPOSITE SHEET MATERIAL COMPRISING SEPARATORS AND SCINTILLATORS ENTRAPPED IN POROUS MATRIX OR MEMBRANE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1032850-A1 | SELF-SCINTILLATING SHEET MATERIAL FOR RADIOACTIVE SPECIES ANALYSIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999027387-A1 | SELF-SCINTILLATING SHEET MATERIAL FOR RADIOACTIVE SPECIES ANALYSIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0280652-B1 | PROCESS FOR INCREASING THE DEGREE OF WHITENESS OF TEXTILE MATERIAL CONTAINING A POLYESTER | CIBA-GEIGY AG (CH) | 1992-09-16 | — | — | EP | disclosed |
| US-4830763-A | Process for increasing the degree of whiteness of polyester-containing textile material | CIBA-GEIGY CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0280652-A1 | Process for increasing the degree of whiteness of textile material containing a polyester | CIBA-GEIGY AG (CH) | 1988-08-31 | — | — | EP | disclosed |
| US-4261855-A | OPTICAL BRIGHTENERS, FLUORESCENT DYES | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| US-4113937-A | OPTICAL BRIGHTENERS | CIBA-GEIGY CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885ALDH1A1 1203/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885ALDH1A1 1203/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885RAB9A 4325/4885ALDH1A1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.